Loading...

UDG Healthcare

LSE:UDG
Snowflake Description

Flawless balance sheet with moderate growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
UDG
LSE
£2B
Market Cap
  1. Home
  2. GB
  3. Healthcare
Company description

UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The last earnings update was 25 days ago. More info.


Add to Portfolio Compare Print
UDG Share Price and Events
7 Day Returns
1.9%
LSE:UDG
1.7%
GB Healthcare
0.4%
GB Market
1 Year Returns
-16.6%
LSE:UDG
-33.5%
GB Healthcare
-3.7%
GB Market
UDG Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
UDG Healthcare (UDG) 1.9% 9.7% 21.5% -16.6% 32.1% 115.3%
GB Healthcare 1.7% -5.2% -2.7% -33.5% -16.1% 87.6%
GB Market 0.4% 1% 1.6% -3.7% 19% 3.4%
1 Year Return vs Industry and Market
  • UDG outperformed the Healthcare industry which returned -33.5% over the past year.
  • UDG underperformed the Market in United Kingdom of Great Britain and Northern Ireland which returned -3.7% over the past year.
Price Volatility
UDG
Industry
5yr Volatility vs Market

UDG Value

 Is UDG Healthcare undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of UDG Healthcare to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for UDG Healthcare.

LSE:UDG Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 9 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 6.9%
Perpetual Growth Rate 10-Year GB Government Bond Rate 1.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for LSE:UDG
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year GB Govt Bond Rate 1.2%
Equity Risk Premium S&P Global 7.1%
Healthcare Unlevered Beta Simply Wall St/ S&P Global 0.64
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.638 (1 + (1- 12.5%) (10.48%))
0.797
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.8
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 1.23% + (0.8 * 7.14%)
6.94%

Discounted Cash Flow Calculation for LSE:UDG using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for UDG Healthcare is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

LSE:UDG DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (USD, Millions) Source Present Value
Discounted (@ 6.94%)
2019 98.20 Analyst x1 91.83
2020 106.00 Analyst x2 92.69
2021 119.10 Analyst x1 97.39
2022 -40.00 Analyst x1 -30.59
2023 262.00 Analyst x1 187.34
2024 305.98 Est @ 16.79% 204.59
2025 343.07 Est @ 12.12% 214.50
2026 373.44 Est @ 8.85% 218.34
2027 397.95 Est @ 6.56% 217.57
2028 417.70 Est @ 4.96% 213.55
Present value of next 10 years cash flows $1,507.21
LSE:UDG DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= $417.70 × (1 + 1.23%) ÷ (6.94% – 1.23%)
$7,402.44
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= $7,402.44 ÷ (1 + 6.94%)10
$3,784.55
LSE:UDG Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= $1,507.21 + $3,784.55
$5,291.76
Equity Value per Share
(USD)
= Total value / Shares Outstanding
= $5,291.76 / 248.91
$21.26
LSE:UDG Discount to Share Price
Calculation Result
Exchange Rate USD/GBP
(Reporting currency to currency of LSE:UDG)
0.793
Value per Share
(GBP)
= Value per Share in USD x Exchange Rate (USD/GBP)
= $21.26 x 0.793
£16.87
Value per share (GBP) From above. £16.87
Current discount Discount to share price of £7.32
= -1 x (£7.32 - £16.87) / £16.87
56.6%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

Current Discount
Amount off the current price UDG Healthcare is available for.
Intrinsic value
>50%
Share price is £7.32 vs Future cash flow value of £16.87
Current Discount Checks
For UDG Healthcare to be considered undervalued it must be available for at least 20% below the current price. Less than 40% is even better.
  • UDG Healthcare's share price is below the future cash flow value, and at a moderate discount (> 20%).
  • UDG Healthcare's share price is below the future cash flow value, and at a substantial discount (> 40%).
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for UDG Healthcare's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are UDG Healthcare's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
LSE:UDG PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-03-31) in USD $0.10
LSE:UDG Share Price ** LSE (2019-06-14) in GBP £7.32
LSE:UDG Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.261 $9.23
United Kingdom of Great Britain and Northern Ireland Healthcare Industry PE Ratio Median Figure of 11 Publicly-Listed Healthcare Companies 24.23x
United Kingdom of Great Britain and Northern Ireland Market PE Ratio Median Figure of 789 Publicly-Listed Companies 16.17x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of UDG Healthcare.

LSE:UDG PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= LSE:UDG Share Price ÷ EPS (both in USD)

= 9.23 ÷ 0.10

88.64x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UDG Healthcare is overvalued based on earnings compared to the GB Healthcare industry average.
  • UDG Healthcare is overvalued based on earnings compared to the United Kingdom of Great Britain and Northern Ireland market.
Price based on expected Growth
Does UDG Healthcare's expected growth come at a high price?
Raw Data
LSE:UDG PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 88.64x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts
16.9%per year
United Kingdom of Great Britain and Northern Ireland Healthcare Industry PEG Ratio Median Figure of 9 Publicly-Listed Healthcare Companies 1.37x
United Kingdom of Great Britain and Northern Ireland Market PEG Ratio Median Figure of 576 Publicly-Listed Companies 1.48x

*Line of best fit is calculated by linear regression .

LSE:UDG PEG (Price to Earnings to Growth) Ratio Calculation
Calculation Outcome
PEG Ratio

= PE Ratio ÷ Net Income Annual Growth Rate

= 88.64x ÷ 16.9%

5.25x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UDG Healthcare is poor value based on expected growth next year.
Price based on value of assets
What value do investors place on UDG Healthcare's assets?
Raw Data
LSE:UDG PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-03-31) in USD $3.59
LSE:UDG Share Price * LSE (2019-06-14) in GBP £7.32
LSE:UDG Share Price converted to USD reporting currency Exchange rate (GBP/ USD) 1.261 $9.23
United Kingdom of Great Britain and Northern Ireland Healthcare Industry PB Ratio Median Figure of 16 Publicly-Listed Healthcare Companies 1.28x
United Kingdom of Great Britain and Northern Ireland Market PB Ratio Median Figure of 1,371 Publicly-Listed Companies 1.48x
LSE:UDG PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= LSE:UDG Share Price ÷ Book Value per Share (both in USD)

= 9.23 ÷ 3.59

2.57x

* Primary Listing of UDG Healthcare.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • UDG Healthcare is overvalued based on assets compared to the GB Healthcare industry average.
X
Value checks
We assess UDG Healthcare's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare industry average (and greater than 0)? (1 check)
  5. UDG Healthcare has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

UDG Future Performance

 How is UDG Healthcare expected to perform in the next 1 to 3 years based on estimates from 9 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
16.9%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is UDG Healthcare expected to grow at an attractive rate?
  • UDG Healthcare's earnings growth is expected to exceed the low risk savings rate of 1.2%.
Growth vs Market Checks
  • UDG Healthcare's earnings growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
  • UDG Healthcare's revenue growth is expected to exceed the United Kingdom of Great Britain and Northern Ireland market average.
Annual Growth Rates Comparison
Raw Data
LSE:UDG Future Growth Rates Data Sources
Data Point Source Value (per year)
LSE:UDG Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 9 Analysts 16.9%
LSE:UDG Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 9 Analysts 5.9%
United Kingdom of Great Britain and Northern Ireland Healthcare Industry Earnings Growth Rate Market Cap Weighted Average 24.8%
United Kingdom of Great Britain and Northern Ireland Healthcare Industry Revenue Growth Rate Market Cap Weighted Average 8.9%
United Kingdom of Great Britain and Northern Ireland Market Earnings Growth Rate Market Cap Weighted Average 10.7%
United Kingdom of Great Britain and Northern Ireland Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
LSE:UDG Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
LSE:UDG Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-09-30 1,663 200 145 2
2022-09-30 1,567 187 136 2
2021-09-30 1,454 167 122 6
2020-09-30 1,380 161 108 9
2019-09-30 1,300 160 90 9
LSE:UDG Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2019-03-31 1,297 101 26
2018-12-31 1,306 102 15
2018-09-30 1,315 103 4
2018-06-30 1,316 108 23
2018-03-31 1,316 114 42
2017-12-31 1,268 111 57
2017-09-30 1,220 108 72
2017-06-30 1,172 106 73
2017-03-31 1,124 105 73
2016-12-31 1,104 89 71
2016-09-30 1,083 74 68
2016-06-30 1,049 113 63

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • UDG Healthcare's earnings are expected to grow by 16.9% yearly, however this is not considered high growth (20% yearly).
  • UDG Healthcare's revenue is expected to grow by 5.9% yearly, however this is not considered high growth (20% yearly).
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
LSE:UDG Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below

All data from UDG Healthcare Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:UDG Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-09-30 0.57 0.66 0.48 2.00
2022-09-30 0.53 0.60 0.46 2.00
2021-09-30 0.48 0.53 0.43 2.00
2020-09-30 0.42 0.44 0.39 4.00
2019-09-30 0.36 0.39 0.32 4.00
LSE:UDG Past Financials Data
Date (Data in USD Millions) EPS *
2019-03-31 0.10
2018-12-31 0.06
2018-09-30 0.02
2018-06-30 0.09
2018-03-31 0.17
2017-12-31 0.23
2017-09-30 0.29
2017-06-30 0.29
2017-03-31 0.30
2016-12-31 0.29
2016-09-30 0.28
2016-06-30 0.26

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • UDG Healthcare is not expected to efficiently use shareholders’ funds in the future (Return on Equity less than 20%).
X
Future performance checks
We assess UDG Healthcare's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the United Kingdom of Great Britain and Northern Ireland market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
UDG Healthcare has a total score of 3/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

UDG Past Performance

  How has UDG Healthcare performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare UDG Healthcare's growth in the last year to its industry (Healthcare).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • UDG Healthcare's year on year earnings growth rate was negative over the past 5 years and the most recent earnings are below average.
  • UDG Healthcare's 1-year earnings growth is negative, it can't be compared to the 5-year average.
  • UDG Healthcare's 1-year earnings growth is negative, it can't be compared to the GB Healthcare industry average.
Earnings and Revenue History
UDG Healthcare's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from UDG Healthcare Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

LSE:UDG Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-03-31 1,296.52 25.89 222.05
2018-12-31 1,305.85 14.84 228.27
2018-09-30 1,315.19 3.80 234.50
2018-06-30 1,315.69 22.84 232.22
2018-03-31 1,316.20 41.89 229.95
2017-12-31 1,267.98 56.87 222.87
2017-09-30 1,219.76 71.86 215.78
2017-06-30 1,172.03 72.60 210.35
2017-03-31 1,124.30 73.34 204.93
2016-12-31 1,103.87 70.73 201.67
2016-09-30 1,083.44 68.11 198.41
2016-06-30 1,048.68 62.84 195.46
2016-03-31 1,076.76 57.11 160.26
2015-12-31 1,025.09 49.32 169.60
2015-09-30 1,025.92 44.16 186.76
2015-03-31 181.62 105.04 199.53
2014-12-31 564.84 118.21 232.53
2014-09-30 964.51 123.09 250.50
2014-06-30 2,863.92 93.82 351.04
2014-03-31 2,834.32 36.76 337.97
2013-12-31 2,816.24 37.34 332.73
2013-09-30 2,751.61 37.28 322.05
2013-06-30 2,591.09 42.22 307.37
2013-03-31 2,502.88 47.94 301.05
2012-12-31 2,494.28 56.11 302.08
2012-09-30 2,350.49 61.26 286.74
2012-06-30 2,267.39 54.97 272.73

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • UDG Healthcare has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • UDG Healthcare used its assets less efficiently than the GB Healthcare industry average last year based on Return on Assets.
  • UDG Healthcare has improved its use of capital last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess UDG Healthcare's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
UDG Healthcare has a total score of 1/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

UDG Health

 How is UDG Healthcare's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up UDG Healthcare's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • UDG Healthcare is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • UDG Healthcare's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of UDG Healthcare's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 2.4x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from UDG Healthcare Company Filings, last reported 2 months ago.

LSE:UDG Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-03-31 892.68 240.70 171.92
2018-12-31 892.68 240.70 171.92
2018-09-30 885.34 243.69 182.57
2018-06-30 885.34 243.69 182.57
2018-03-31 875.52 257.54 210.94
2017-12-31 875.52 257.54 210.94
2017-09-30 880.66 244.49 189.92
2017-06-30 880.66 244.49 189.92
2017-03-31 819.57 305.61 377.10
2016-12-31 819.57 305.61 377.10
2016-09-30 806.88 306.99 436.97
2016-06-30 802.88 305.47 434.80
2016-03-31 669.51 488.43 213.51
2015-12-31 638.46 465.78 203.60
2015-09-30 679.40 487.31 244.21
2015-03-31 625.29 488.54 161.42
2014-12-31 704.53 550.46 181.88
2014-09-30 673.54 513.39 202.35
2014-06-30 730.62 556.89 219.50
2014-03-31 571.07 599.79 132.28
2013-12-31 570.75 599.46 132.21
2013-09-30 567.72 560.51 238.62
2013-06-30 545.28 538.36 229.19
2013-03-31 522.39 414.11 126.72
2012-12-31 537.54 426.12 130.40
2012-09-30 550.22 376.28 92.36
2012-06-30 543.11 371.42 91.17
  • UDG Healthcare's level of debt (27%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (104.6% vs 27% today).
  • Debt is well covered by operating cash flow (41.8%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 16x coverage).
X
Financial health checks
We assess UDG Healthcare's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. UDG Healthcare has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

UDG Dividends

 What is UDG Healthcare's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
1.73%
Current annual income from UDG Healthcare dividends. Estimated to be 2.09% next year.
If you bought £2,000 of UDG Healthcare shares you are expected to receive £35 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • UDG Healthcare's pays a lower dividend yield than the bottom 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (1.97%).
  • UDG Healthcare's dividend is below the markets top 25% of dividend payers in United Kingdom of Great Britain and Northern Ireland (5.43%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
LSE:UDG Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 9 Analyst Estimates (S&P Global) See Below
United Kingdom of Great Britain and Northern Ireland Healthcare Industry Average Dividend Yield Market Cap Weighted Average of 11 Stocks 1.7%
United Kingdom of Great Britain and Northern Ireland Market Average Dividend Yield Market Cap Weighted Average of 705 Stocks 4.3%
United Kingdom of Great Britain and Northern Ireland Minimum Threshold Dividend Yield 10th Percentile 1.1%
United Kingdom of Great Britain and Northern Ireland Bottom 25% Dividend Yield 25th Percentile 2%
United Kingdom of Great Britain and Northern Ireland Top 25% Dividend Yield 75th Percentile 5.4%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

LSE:UDG Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2023-09-30 0.24 3.00
2022-09-30 0.22 3.00
2021-09-30 0.20 7.00
2020-09-30 0.19 11.00
2019-09-30 0.17 9.00
LSE:UDG Past Annualized Dividends Data
Date (Data in $) Dividend per share (annual) Avg. Yield (%)
2019-03-04 0.160 1.933
2018-05-22 0.140 1.574
2017-12-19 0.133 1.129
2017-11-28 0.133 1.156
2016-12-16 0.120 1.302
2016-11-24 0.120 1.471
2015-12-18 0.116 1.503
2015-11-24 0.116 1.437
2014-12-18 0.107 1.537
2014-11-20 0.124 2.166
2014-01-06 0.119 2.236
2013-11-21 0.129 2.535
2013-05-09 0.117 2.385
2013-01-11 0.116 2.744
2012-11-14 0.115 2.806
2011-12-19 0.105 3.793
2011-11-16 0.112 4.382
2010-12-17 0.109 3.723
2010-11-17 0.109 4.036
2009-11-30 0.096 3.429
2009-11-18 0.119 3.534

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of UDG Healthcare's earnings are paid to the shareholders as a dividend.
  • Dividends paid are not well covered by earnings (0.6x coverage).
Future Payout to shareholders
  • Dividends after 3 years are expected to be well covered by earnings (3x coverage).
X
Income/ dividend checks
We assess UDG Healthcare's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 1.1%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can UDG Healthcare afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. UDG Healthcare has a total score of 3/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

UDG Management

 What is the CEO of UDG Healthcare's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Brendan McAtamney
COMPENSATION $1,995,000
AGE 55
TENURE AS CEO 3.3 years
CEO Bio

Mr. Brendan McAtamney has been the Chief Executive Officer of UDG Healthcare plc since February 2, 2016 and has been an Executive Director since December 16, 2013. Mr. McAtamney has been a Non-Executive Director at Scapa Group plc since February 01, 2018. He served as the Group Chief Operating Officer of UDG Healthcare plc since September 2013 until February 2, 2016. He joined UDG Healthcare in September 1, 2013 as Chief Operating Officer. He held various senior management positions with Abbott, latterly as Vice President Commercial and Corporate Officer within the Established Pharmaceuticals Division. He has been a Director of UDG Healthcare plc, Aquilant Analytical Sciences Ltd., Aquilant Medical (ROI) Ltd., Aquilant Scientific (ROI) Ltd., UDG Healthcare Ireland Ltd., UDG Healthcare Ayrtons (Dublin) Ltd since December 16, 2013, Aquilant Ltd October 30, 2013, Aquilant Scientific (UK) Ltd since October 30, 2013, Ashfield Healthcare Ltd February 3, 2016, Unitech Equipment Ltd since October 30, 2013 and UDG Healthcare (UK) Holdings Ltd. He served as a Director of Abbott Laboratories GmbH from 31 May 2010 to 31 July 2013; Abbott Products GmbH from 31 May 2010 to 31 July 2013; Abbott Laboratories from 28 February 2010 to 31 July 2013; Abbott Laboratories Inc. from 28 February 2010 to 31 July 2013; Laboratoires Fournier S.A.S from 31 May 2010 to 8 January 2013 and Abbott Truecare Pharma Private Ltd. from May 31, 2010 to July 31, 2013.

CEO Compensation
  • Brendan's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Brendan's remuneration is higher than average for companies of similar size in United Kingdom of Great Britain and Northern Ireland.
Management Team Tenure

Average tenure and age of the UDG Healthcare management team in years:

2.8
Average Tenure
48
Average Age
  • The tenure for the UDG Healthcare management team is about average.
Management Team

Brendan McAtamney

TITLE
CEO & Executive Director
COMPENSATION
$2M
AGE
55
TENURE
3.3 yrs

Nigel Clerkin

TITLE
CFO & Executive Director
COMPENSATION
$574K
AGE
44
TENURE
1.1 yrs

Keith Byrne

TITLE
Head of Investor Relations

Eleanor Garvey

TITLE
Group Head of Quality & Compliance

Damien Moynagh

TITLE
General Counsel & Company Secretary

Liam Logue

TITLE
Executive Vice President of Corporate Development
TENURE
5.7 yrs

Eimear Kenny

TITLE
Group Head of Human Resources
AGE
48

Tom Mitchell

TITLE
Uk Head of Syndicated Services for Ashfield
TENURE
2.2 yrs

Mike O'Hara

TITLE
MD & President of Sharp Packaging

Julian Tompkins

TITLE
President of Ashfield Commercial & Clinical
Board of Directors Tenure

Average tenure and age of the UDG Healthcare board of directors in years:

5.5
Average Tenure
59
Average Age
  • The tenure for the UDG Healthcare board of directors is about average.
Board of Directors

Peter Gray

TITLE
Chairman of the Board
COMPENSATION
$208K
AGE
63
TENURE
7.3 yrs

Brendan McAtamney

TITLE
CEO & Executive Director
COMPENSATION
$2M
AGE
55
TENURE
5.5 yrs

Nigel Clerkin

TITLE
CFO & Executive Director
COMPENSATION
$574K
AGE
44
TENURE
1.1 yrs

Chris Brinsmead

TITLE
Non–Executive Director
COMPENSATION
$94K
AGE
59
TENURE
9.2 yrs

Linda Wilding

TITLE
Non-Executive Director
COMPENSATION
$84K
AGE
59
TENURE
5.5 yrs

Myles Lee

TITLE
Senior Independent Director
COMPENSATION
$82K
AGE
65
TENURE
0.1 yrs

Chris Corbin

TITLE
Non-Executive Director
COMPENSATION
$1M
AGE
63
TENURE
16 yrs

Lisa Ricciardi

TITLE
Non-Executive Director
COMPENSATION
$68K
AGE
58
TENURE
6 yrs

Nancy Miller-Rich

TITLE
Non-Executive Director
COMPENSATION
$68K
AGE
59
TENURE
3 yrs

Erik Van Snippenberg

TITLE
Non-Executive Director
COMPENSATION
$17K
AGE
54
TENURE
0.9 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (£) Value (£)
04. Feb 19 Buy Erik Van Snippenberg Individual 01. Feb 19 01. Feb 19 7,500 £5.87 £44,025
16. Jan 19 Buy Lisa Ricciardi Individual 14. Jan 19 14. Jan 19 6,745 £5.75 £38,767
28. Nov 18 Buy Myles Lee Individual 27. Nov 18 27. Nov 18 6,000 £5.90 £35,400
21. Sep 18 Buy Brendan McAtamney Individual 20. Sep 18 20. Sep 18 35,000 £6.60 £231,000
20. Sep 18 Buy Peter Gray Individual 19. Sep 18 19. Sep 18 14,000 £6.31 £88,340
13. Aug 18 Buy Myles Lee Individual 09. Aug 18 09. Aug 18 4,000 £7.52 £30,080
X
Management checks
We assess UDG Healthcare's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. UDG Healthcare has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

UDG News

Simply Wall St News

UDG Healthcare (LON:UDG) Shareholders Have Enjoyed An Impressive 105% Share Price Gain

One great example is UDG Healthcare plc (LON:UDG) which saw its share price drive 105% higher over five years. … By comparing earnings per share (EPS) and share price changes over time, we can get a feel for how investor attitudes to a company have morphed over time. … UDG Healthcare's earnings per share are down 7.3% per year, despite strong share price performance over five years.

Simply Wall St -

Only 2 Days Left Until UDG Healthcare plc (LON:UDG) Trades Ex-Dividend

To qualify for the dividend check of US$0.045 per share, investors must have owned the shares prior to 30 May 2019, which is the last day the company's management will finalize their list of shareholders to which they will send dividend payments. … Investors looking for higher income-generating stocks to add to their portfolio should keep reading, as I examine UDG Healthcare's latest financial data to analyse its dividend characteristics. … View our latest analysis for UDG Healthcare 5 questions I ask before picking a dividend stock When researching a dividend stock, I always follow the following screening criteria: Does it pay an annual yield higher than 75% of dividend payers?

Simply Wall St -

Need To Know: UDG Healthcare plc (LON:UDG) Insiders Have Been Selling Shares

So we'll take a look at whether insiders have been buying or selling shares in UDG Healthcare plc (LON:UDG). … LSE:UDG Recent Insider Trading, May 16th 2019 If you like to buy stocks that insiders are buying, rather than selling, then you might just love this free list of companies. … Insider Ownership Another way to test the alignment between the leaders of a company and other shareholders is to look at how many shares they own.

Simply Wall St -

Is UDG Healthcare plc (LON:UDG) A Risky Dividend Stock?

Today we'll take a closer look at UDG Healthcare plc (LON:UDG) from a dividend investor's perspective. … Owning a strong dividend company and reinvesting the dividends is widely seen as an attractive way of growing your wealth. … Investors might not know much about UDG Healthcare's dividend prospects, even though it has been paying dividends for the last nine years and offers a 1.8% yield.

Simply Wall St -

Is UDG Healthcare plc (LON:UDG) A Financially Strong Company?

Mid-caps stocks, like UDG Healthcare plc (LON:UDG) with a market capitalization of UK£1.6b, aren’t the focus of most investors who prefer to direct their investments towards either large-cap or small-cap stocks. … While they are less talked about as an investment category, mid-cap risk-adjusted returns have generally been better than more commonly focused stocks that fall into the small- or large-cap categories. … Let’s take a look at UDG’s debt concentration and assess their financial liquidity to get an idea of their ability to fund strategic acquisitions and grow through cyclical pressures.

Simply Wall St -

You Might Like UDG Healthcare plc (LON:UDG) But Do You Like Its Debt?

While investors primarily focus on the growth potential and competitive landscape of the small-cap companies, they end up ignoring a key aspect, which could be the biggest threat to its existence: its financial health. … Understanding the company's financial health becomes. … Let's work through some financial health checks you may wish to consider if you're interested in this stock.

Simply Wall St -

UDG Healthcare plc (LON:UDG) Might Not Be A Great Investment

Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. … What is Return On Capital Employed (ROCE)? … ROCE measures the amount of pre-tax profits a company can generate from the capital employed in its business.

Simply Wall St -

Should We Be Cautious About UDG Healthcare plc's (LON:UDG) ROE Of 0.4%?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … Our data shows UDG Healthcare has a return on equity of 0.4% for the last year. … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Are Insiders Selling UDG Healthcare plc (LON:UDG) Stock?

So we'll take a look at whether insiders have been buying or selling shares in UDG Healthcare plc (LON:UDG). … UDG Healthcare Insider Transactions Over The Last Year. … In the last twelve months, the biggest single sale by an insider was when Non-Executive Director Chris Corbin sold UK£6.8m worth of shares at a price of UK£9.03 per share.

Simply Wall St -

How Much Did UDG Healthcare plc's (LON:UDG) CEO Pocket Last Year?

How Does Brendan McAtamney's Compensation Compare With Similar Sized Companies. … According to our data, UDG Healthcare plc has a market capitalization of UK£1.5b, and pays its CEO total annual compensation worth US$2.0m. … We looked at a group of companies with market capitalizations from €877m to €2.8b, and the median CEO compensation was €1.7m.

Simply Wall St -

UDG Company Info

Description

UDG Healthcare plc, together with its subsidiaries, provides advisory, communication, commercial, clinical, and packaging services in the Republic of Ireland, the United Kingdom, North America, and internationally. The company operates in two segments, Ashfield and Sharp. The Ashfield segment offers commercialization services for the pharmaceutical and healthcare industry in the areas of advisory, communications, and commercial and clinical services. This segment supports healthcare professionals and patients at various stages of the product life cycle; and provides field and contact center sales teams, healthcare communications, patient support, audit, advisory, medical information, and event management services to approximately 300 healthcare companies. The Sharp segment provides contract and clinical trial packaging services for the pharmaceutical and biotechnology industries; and serialization solutions. The company was formerly known as United Drug plc and changed its name to UDG Healthcare plc in August 2013. UDG Healthcare plc was founded in 1948 and is based in Dublin, the Republic of Ireland.

Details
Name: UDG Healthcare plc
UDG
Exchange: LSE
Founded: 1948
£1,822,042,662
248,912,932
Website: http://www.udghealthcare.com
Address: UDG Healthcare plc
20 Riverwalk,
Citywest Business Campus,
Dublin,
Co. Dublin, 24,
Ireland
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
LSE UDG Ordinary Shares London Stock Exchange GB GBP 02. Jan 1992
OTCPK UDHC.F Ordinary Shares Pink Sheets LLC US USD 02. Jan 1992
DB UN6A Ordinary Shares Deutsche Boerse AG DE EUR 02. Jan 1992
BATS-CHIXE UDGL Ordinary Shares BATS 'Chi-X Europe' GB GBP 02. Jan 1992
OTCPK UDRG.Y ADR Pink Sheets LLC US USD 28. Oct 2008
Number of employees
Current staff
Staff numbers
9,000
UDG Healthcare employees.
Industry
Health Care Services
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 20:53
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/06/10
Last earnings filing: 2019/05/21
Last earnings reported: 2019/03/31
Last annual earnings reported: 2018/09/30


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.